-
New Study Points to SX-682 as Novel Strategy to Broadly Increase the Effectiveness of Therapies Targeting the RAS/RAF/MEK/ERK Signaling Pathway in Non-Small Cell Lung Cancer
-A new study led by researchers at NYU Grossman School of Medicine and its Laura and Isaac Perlmutter Cancer Center…
0 -
Two New Reports Show SX-682 Blocks Key Immunosuppressive Tumor Cells to Enhance Checkpoint Inhibitors and NK-Based Cell Immunotherapies
-Researchers at the Fred Hutchinson Cancer Research Center and the National Institutes of Health (NIH) independently showed SX-682 eradicates pivotal…
-
Syntrix Pharmaceuticals to Present Positive Desmetramadol Trial Results at the 2019 Pain Management SUMMIT
-Desmetramadol trial featured on the October cover of The Journal of Pain AUBURN, WASHINGTON — Syntrix Pharmaceuticals, Inc., a leading…
-
Syntrix Announces Dosing of First Patient in Phase 1/2 Clinical Trial of SX-682 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Melanoma
-– Initial Clinical Data Expected in First Half of 2020 – AUBURN, WASHINGTON — Syntrix Pharmaceuticals today announced that it…
-
Syntrix Reports Positive Clinical Trials Showing Desmetramadol Has the Analgesic and Side Effect Profile of Tramadol Without Its Metabolic Liabilities
-Study successfully met its endpoints and provides basis for pivotal Phase 3 trial AUBURN, WASHINGTON — Syntrix Pharmaceuticals today announced…
-
Researchers Report SX-682 Could Enhance Multiple Forms of T Cell-Based Immunotherapies in Solid Tumors
-Researchers at the National Institutes of Health (NIH) have shown that inhibition of myeloid-derived suppressor cell (MDSC) trafficking into mouse…
-
New Study Points to SX-682 as Strategy to Boost Immunotherapy Effectiveness in Advanced Colorectal Cancer
-AUBURN, WASHINGTON — In collaboration with Syntrix Pharmaceuticals, researchers at the University of Texas MD Anderson Cancer Center revealed that…
-
Syntrix Announces First Patient Cohort Dosed in Phase 2 Study of Desmetramadol in Diabetic Neuropathic Pain
-AUBURN, WASHINGTON — Syntrix Pharmaceuticals today announced the initiation of a Phase 2 study evaluating the efficacy and safety of…
-
Syntrix Wins $3.4M NIH Grant to Conduct Phase 1/2 trial of SX-682 in Myelodysplastic Syndrome
-AUBURN, WASHINGTON — Syntrix Pharmaceuticals announced this week that it has been awarded a three-year grant worth $3.4 million from…
-
Desmetramadol featured today in new article by Research Outreach
-Desmetramadol featured today in new article by Research Outreach entitled, “Moving beyond dangerous opioids for pain: Syntrix creates new drug…
Author archive for Syntrix
Syntrix Pharmaceuticals > Articles by: Syntrix
